Tags

Type your tag names separated by a space and hit enter

Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
J Cardiovasc Pharmacol Ther. 2008 Sep; 13(3):183-8.JC

Abstract

We analyzed the feasibility of an intensive lipid-lowering strategy based on a starting dose of atorvastatin according to baseline and target low-density lipoprotein cholesterol (LDL-C) level (<2.6 mmol/L) in 202 statin-naïve patients with type 2 diabetes within 24 weeks. They were assigned to receive a daily dosage of atorvastatin based on their initial LDL-C levels. The primary endpoint was the proportion of patients achieving the LDL-C goal after 24 weeks of treatment. No changes were made in prescribed atorvastatin dosage. At the study end, 66.5% of the 188 patients completing the trial reached the LDL-C target (75%, 67%, 58% and 59% with 10, 20, 40 and 80 mg per day of atorvastatin, respectively) reached LDL-C target. Atorvastatin reduced the levels of total cholesterol, LDL-C, high density lipoprotein cholesterol (HDL-C) and triglycerides by 29%, 35%, 3% and 22%, respectively, and all statin doses were well tolerated. Thus, individualizing the starting dose of atorvastatin according to baseline and target LDL-C levels, allowed a high proportion of type 2 diabetic patients to achieve the target within 24 weeks.

Authors+Show Affiliations

Division of Diabetes, Consortium University General Hospital of Valencia, Spain. ferrer_juagar@gva.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

18635754

Citation

Ferrer-García, Juan Carlos, et al. "Efficacy of Atorvastatin for Achieving Cholesterol Targets After LDL-cholesterol Based Dose Selection in Patients With Type 2 Diabetes." Journal of Cardiovascular Pharmacology and Therapeutics, vol. 13, no. 3, 2008, pp. 183-8.
Ferrer-García JC, Sanchez-Ballester E, Albalat-Galera R, et al. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther. 2008;13(3):183-8.
Ferrer-García, J. C., Sanchez-Ballester, E., Albalat-Galera, R., Berzosa-Sanchez, M., & Herrera-Ballester, A. (2008). Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. Journal of Cardiovascular Pharmacology and Therapeutics, 13(3), 183-8. https://doi.org/10.1177/1074248408321461
Ferrer-García JC, et al. Efficacy of Atorvastatin for Achieving Cholesterol Targets After LDL-cholesterol Based Dose Selection in Patients With Type 2 Diabetes. J Cardiovasc Pharmacol Ther. 2008;13(3):183-8. PubMed PMID: 18635754.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. AU - Ferrer-García,Juan Carlos, AU - Sanchez-Ballester,Eva, AU - Albalat-Galera,Raquel, AU - Berzosa-Sanchez,Miguel, AU - Herrera-Ballester,Agustín, Y1 - 2008/07/17/ PY - 2008/7/19/pubmed PY - 2008/12/19/medline PY - 2008/7/19/entrez SP - 183 EP - 8 JF - Journal of cardiovascular pharmacology and therapeutics JO - J Cardiovasc Pharmacol Ther VL - 13 IS - 3 N2 - We analyzed the feasibility of an intensive lipid-lowering strategy based on a starting dose of atorvastatin according to baseline and target low-density lipoprotein cholesterol (LDL-C) level (<2.6 mmol/L) in 202 statin-naïve patients with type 2 diabetes within 24 weeks. They were assigned to receive a daily dosage of atorvastatin based on their initial LDL-C levels. The primary endpoint was the proportion of patients achieving the LDL-C goal after 24 weeks of treatment. No changes were made in prescribed atorvastatin dosage. At the study end, 66.5% of the 188 patients completing the trial reached the LDL-C target (75%, 67%, 58% and 59% with 10, 20, 40 and 80 mg per day of atorvastatin, respectively) reached LDL-C target. Atorvastatin reduced the levels of total cholesterol, LDL-C, high density lipoprotein cholesterol (HDL-C) and triglycerides by 29%, 35%, 3% and 22%, respectively, and all statin doses were well tolerated. Thus, individualizing the starting dose of atorvastatin according to baseline and target LDL-C levels, allowed a high proportion of type 2 diabetic patients to achieve the target within 24 weeks. SN - 1074-2484 UR - https://www.unboundmedicine.com/medline/citation/18635754/Efficacy_of_atorvastatin_for_achieving_cholesterol_targets_after_LDL_cholesterol_based_dose_selection_in_patients_with_type_2_diabetes_ L2 - https://journals.sagepub.com/doi/10.1177/1074248408321461?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -